AIM Vaccine Co., Ltd. engages in biological vaccine technology development, technology transfer, and technical services. Its products include Recombinant hepatitis B vaccine, Freeze-dried Human Rabies vaccine, Inactivated Hepatitis A vaccine, Live Attenuated Parotitis vaccine, Inactivated HFRS vaccine, and ACYW135 Meningococcus Polysaccharide vaccine. The company was founded on November 9, 2011 and is headquartered in Beijing, China.